VNDA (Vanda Pharmaceuticals) Cyclically Adjusted Book per Share: $8.15 (As of Mar. 2026)


VNDA Vanda Pharmaceuticals Inc VNDA
74 GF Score
Price $6.05
GF Value $5.50
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Cyclically Adjusted Book per Share?

Vanda Pharmaceuticals VNDA -1.14% 74 Cyclically Adjusted Book per Share is $8.15 as of Mar. 2026. GuruFocus rates VNDA with a GF Score™ of 74/100 and a GF Value™ of $5.50 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $4.669. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.15 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vanda Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 6.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 13.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 18.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vanda Pharmaceuticals was 26.80% per year. The lowest was 5.80% per year. And the median was 19.60% per year.

As of today (2026-07-01), Vanda Pharmaceuticals's current stock price is $6.05. Vanda Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $8.15. Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.74.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vanda Pharmaceuticals was 14.44. The lowest was 0.51. And the median was 3.84.


Vanda Pharmaceuticals  (NAS:VNDA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=6.05/8.15
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vanda Pharmaceuticals was 14.44. The lowest was 0.51. And the median was 3.84.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vanda Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Vanda Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Cyclically Adjusted Book per Share Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.38 5.50 6.52 7.49 7.98

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.68 7.84 7.97 7.98 8.15

VNDA vs AVIR, OABI, TENX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


VNDA
74GF Score
Vanda Pharmaceuticals Inc VNDA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vanda Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.669/330.2130*330.2130
=4.669

Current CPI (Mar. 2026) = 330.2130.

Vanda Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.810 241.018 3.850
201609 2.940 241.428 4.021
201612 2.985 241.432 4.083
201703 2.877 243.801 3.897
201706 2.930 244.955 3.950
201709 2.904 246.819 3.885
201712 2.924 246.524 3.917
201803 4.628 249.554 6.124
201806 4.797 251.989 6.286
201809 4.989 252.439 6.526
201812 5.248 251.233 6.898
201903 5.257 254.202 6.829
201906 5.570 256.143 7.181
201909 7.517 256.759 9.667
201912 7.674 256.974 9.861
202003 7.692 258.115 9.841
202006 7.900 257.797 10.119
202009 8.056 260.280 10.221
202012 8.261 260.474 10.473
202103 8.417 264.877 10.493
202106 8.651 271.696 10.514
202109 8.855 274.310 10.660
202112 9.033 278.802 10.699
202203 8.889 287.504 10.209
202206 8.993 296.311 10.022
202209 9.112 296.808 10.138
202212 9.284 296.797 10.329
202303 9.327 301.836 10.204
202306 9.390 305.109 10.163
202309 9.440 307.789 10.128
202312 9.471 306.746 10.196
202403 9.347 312.332 9.882
202406 9.308 314.175 9.783
202409 9.282 315.301 9.721
202412 9.236 315.605 9.663
202503 8.678 319.799 8.961
202506 8.232 322.561 8.427
202509 7.885 324.800 8.016
202512 5.536 324.054 5.641
202603 4.669 330.213 4.669

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $8.15 mean?
Vanda Pharmaceuticals (VNDA) has a Cyclically Adjusted Book per Share of $8.15 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Vanda Pharmaceuticals' current Cyclically Adjusted Book per Share is $8.15. Overall, Vanda Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Cyclically Adjusted Book per Share compare to AVIR and OABI?
Vanda Pharmaceuticals' Cyclically Adjusted Book per Share of $8.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Cyclically Adjusted Book per Share is $8.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Fairly Valued. The stock's GF Value™ is $5.50, compared to a current price of $6.05 — trading 10% above its estimated fair value. The current Cyclically Adjusted Book per Share is $8.15. Vanda Pharmaceuticals' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Cyclically Adjusted Book per Share is $8.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of $6.05 is trading 10% above its estimated GF Value™ of $5.50. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for VNDA:

  • Cyclically Adjusted Book per Share: $8.15
  • GF Value™: $5.50 vs. price of $6.05 (10% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vanda Pharmaceuticals Business Description

Other Exchanges 0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
74GF Score

Get the complete analysis for VNDA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.05
Price
$5.50
GF Value